Astrazeneca

Cambridge, United Kingdom Founded: 1913 • Age: 113 yrs Listed
Pharmaceutical and biologics products are developed and distributed worldwide.
Request Access
Report Incorrect Data
Page last updated

About Astrazeneca

Astrazeneca is a publicly listed company based in Cambridge (United Kingdom) founded in 1913. Pharmaceutical and biologics products are developed and distributed worldwide. The company has 77,642 employees. Astrazeneca has completed 23 acquisitions, including Acerta Pharma, Alexion and Amolyt Pharma. Its chief executive, as recorded, is Pascal Soirot. Its website astrazeneca.com draws about 1.3 million monthly visits. Its Indian entity Astrazeneca Pharma India Limited reported revenue of ₹2,304 Cr. Astrazeneca offers products and services including Enhertu and Cardiovascular Medicines. Its focus areas include Diversified Pharmaceuticals and Drugs.

Company details

AstraZeneca was established in 1913 and operates as a multinational pharmaceutical and biologics firm headquartered in Cambridge, United Kingdom. Operations span over 100 countries, with a focus on products addressing cancer, cardiovascular, gastrointestinal, infectious, neurological, respiratory, and inflammatory conditions. The company has grown through mergers and acquisitions, including Cambridge Antibody Technology in 2006 and MedImmune in 2007, achieving annual revenues of 43.85 billion in 2022.

  • Headquarters Cambridge, United Kingdom
  • Employees 77,642
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website astrazeneca.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Legal Name Astrazeneca Pharma India Limited
Operational Areas
Healthcare → Pharmaceuticals & Distribution
Key Metrics
  • Market Cap
    ₹16,286 Cr

    ASTRAZEN · NSE

  • Share Price
    ₹6,514.50

    +0.54% today

  • Revenue
    ₹2,276 Cr

    FY 2025-26 · +32.6% YoY

  • EBITDA
    ₹257 Cr

    Margin 11.3%

  • Net Profit
    ₹191 Cr

    FY 2025-26 · +9.2% YoY

  • P/E (TTM)
    84.7x

    P/B 18.1x

  • ROE
    22.8%

    ROCE 27.9%

  • Debt / Equity
    0.09

    Interest cover 2.0x

  • Latest Funding Round
    $6.09M (USD), Post-IPO

    Dec 2021

  • Investors
    European Union

    & 5 more

  • Employee Count
    77,642
  • Investments & Acquisitions
    Acerta Pharma

    & 22 more

Products & Services of Astrazeneca

Astrazeneca offers a comprehensive portfolio of products and services, including Enhertu and Cardiovascular Medicines.

Enhertu
Oncology Drug

Targets HER2-positive metastatic breast cancer through antibody-drug conjugates.

Cardiovascular Medicines
Therapeutic Drugs

Addresses heart, renal, and metabolic conditions via innovative research.

Apps and channels of Astrazeneca

its YouTube channel astrazeneca has 19.1K subscribers and 30 videos.

astrazeneca
YouTube 19.1K subscribers 30 videos Science & Technology
Open channel

Videos from Astrazeneca

The most watched videos on Astrazeneca's YouTube channel, astrazeneca (19.1K subscribers). Click a video to play it here.

Why 0.1% of our DNA Matters: Shaping the Future of Medicine
4.2M views
Lung Cancer, Stigma and Me – Series Trailer
64.2K views
High throughput screening at The DISC: a new era of drug discovery
10.3K views
Full Year and Q4 2024 Results
6.3K views

More on astrazeneca.

Funding Insights of Astrazeneca

  • Total Rounds 27
  • Last Round Post-IPO — $6.09M
  • First Round $12M

    (Jan 2011)

  • Investors Count 6

Latest 10 of 27 funding rounds of Astrazeneca with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Dec 2021$6.09MPost-IPO––
Cambridge
May 2021$334,183Grant––
European Union
Jan 2021$371,803Grant––
European Union
Sep 2020$286,743Grant––
European Union
Jul 2020$317,805Grant––
European Union
Jun 2020$23.7MGrant––
USAGov
May 2020$1BGrant––
Public Health Emergency
Feb 2020$328,501Grant––
European Union
Jan 2020$332,175Grant––
European Union
Oct 2019$16,576Grant––
European Union
Valuation history

6 investors in total: 6 institutional.

Investors in Astrazeneca

Astrazeneca has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union, Cambridge and USAGov.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Mission Ventures
VC firm for early-stage startups
missionventures.comSan Diego, United States
Columbia Capital
US tech companies are funded across stages by Columbia Capital.
colcap.comAlexandria, United States
Cambridge
Investment research services are provided to financial clients by Cambridge.
1981joincambridge.comFairfield, United States
European Union
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
1958europa.euBrussels, Belgium
USAGov
Government entity focused on information and services
2000usa.govUnited States
Public Health Emergency
phe.gov
Premium access

Investor details for Astrazeneca

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Astrazeneca Pharma India Limited (Astrazeneca)

Astrazeneca Pharma India Limited is the primary company behind Astrazeneca. The board of Astrazeneca Pharma India Limited currently have 6 directors; the longest-serving is Ashok Revathy, appointed in 2016. 36 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Ashok Revathy
DIN 00057539
Director02 Dec 20169 yrs 11 moAstrazeneca Pharma India Limited
Shilpa Divekar Nirula
DIN 06619353
Director29 Dec 20214 yrs 10 moAstrazeneca Pharma India Limited
Hooi Bien Chuah
DIN 10381891
Director09 Nov 20233 yrsAstrazeneca Pharma India Limited
Bhavana Agrawal
DIN 10485441
Whole-time director08 Feb 20242 yrs 9 moAstrazeneca Pharma India Limited
Monica
DIN 07674403
Director25 Sep 20242 yrs 1 moAstrazeneca Pharma India Limited
Praveen Rao Akkinepally
DIN 11137771
Managing Director01 Jul 20251 yr 4 moAstrazeneca Pharma India Limited

People of Astrazeneca

1287 people are tracked at Astrazeneca (773 in leadership, 13 in board & advisors, 501 in team); the tracked headcount is 77,642.

NameRoleGroup
Pascal Soirot
CEOLeadership
Bastian Sauer-Odendahl
Human Resources DirectorLeadership
Kamila Kozikowski
CFO- Az NetherlandsLeadership
Anna Graham
Chief Financial OfficerLeadership
Gonzalo Izazaga Kuri
CFOLeadership
Arnaud Dubarry
CFOLeadership
Ruud Dobber
EVP & President, BioPharmaceuticals BusinessLeadership
Carla Ruiz Serrano
Human Resources DirectorLeadership
Julia Weigandt
Associate Director, ImmunotoxicologyLeadership
Lan Cao
Head Of Immunology Cell Therapy DiscoveryLeadership
Emma Robbins
Franchise Finance Director - TagrissoLeadership
Bethany Cameron
Director - Business Planning & Operations - Pharmaceutical SciencesLeadership
Laurence Somerville
Clinical Account DirectorLeadership
Mickey S.
Sr. Talent Acquisition Partner-commercial Biopharma (rpo)Leadership
Avijit Majumdar
Associate Director, Translational Science LeadLeadership
Helicia Paz-Chang
Director-translational Sciences BioanalysisLeadership
Maneesh Mishra
DirectorLeadership
Minal Nade-Kulkarni
Director Clinical Operations + RTSM StrategistLeadership
Ya G.
Associate Director, Global Analytics & Insights, OncologyLeadership
Vickie Beckler
US Lung Ambition DirectorLeadership

1267 more people are available in the full profile.

Premium access

Complete people profiles for Astrazeneca

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Astrazeneca

Astrazeneca is a publicly listed company on the NSE with ticker symbol ASTRAZEN in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date13 Jan 2006
  • Listed onLSE: AZN
  • Listed entityAstraZeneca Pharma India Limited
  • Exchange sectorHealth technology
  • ISININE203A01020
  • Share price₹5,950.50 (+1.24% on the day) · 2026-10-14
  • Market capitalisation₹14,718 Cr
  • Price to earnings87.7
  • EPS (diluted, trailing year)₹67.85
  • Dividend yield0.61%
  • Volume (last session)12,179

Financials of Astrazeneca

Exchange-reported figures of Astrazeneca Pharma India Limited, the listed company behind Astrazeneca (NSE: ASTRAZEN).

Financial Highlights

FY 2025-26 · Standalone
Revenue
₹2,276 Cr
+32.6% YoY
EBITDA
₹257 Cr
+63.4% YoY
Profit After Tax
₹191 Cr
+9.2% YoY
Net Worth
₹873 Cr
+13.3% YoY
Total Assets
₹1,021 Cr
+24.3% YoY
Total Debt
₹111 Cr
+209.7% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue2,2761,7161,2961,003806814832
Revenue growth+32.6%+32.5%+29.2%+24.5%-1.0%-2.2%-
EBITDA25715718412586.18135121
EBITDA margin+11.3%+9.2%+14.2%+12.5%+10.7%+16.7%+14.5%
Profit before tax25215622013483.04127114
Net profit19117514912659.5591.7272.03
Net profit margin+8.4%+10.2%+11.5%+12.6%+7.4%+11.3%+8.7%
EPS (₹)75.0146.3064.6039.7224.6437.3228.88
Balance sheet
Total assets1,021821723604528475382
Net worth873770712589511456364
Total debt11135.734.597.218.6312.1411.84
Cash & bank449537506500448352253
Net working capital772646577455377319218
Cash flow
Cash from operations(15.14)65.3627.8758.2910110587.42
Cash from investing18.6930.8021.7418.114.74173(171)
Cash from financing(91.97)(65.59)(44.38)(24.48)(9.46)(8.97)(6.36)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue729683579612559526480440
Revenue growth (YoY)+30.4%+29.7%+20.4%+38.9%+37.0%+35.8%--
Other income15.129.235.956.616.1711.2416.157.98
Total expenses648634519567489446400397
EBITDA80.6148.7059.8344.8369.8980.7580.6943.44
EBITDA margin+11.1%+7.1%+10.3%+7.3%+12.5%+15.3%+16.8%+9.9%
Depreciation5.355.235.603.842.5716.5717.699.07
Interest1.891.952.041.060.670.720.680.33
Profit before tax88.4950.7558.1446.5472.8274.7078.4742.02
Tax26.1612.8213.2613.9518.6018.8720.2211.17

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue729683579612559526480440
Revenue growth (YoY)+30.4%+29.7%+20.4%+38.9%+37.0%+35.8%--
Other income15.129.235.956.616.1711.2416.157.98
Total expenses648634519567489446400397
EBITDA80.6148.7059.8344.8369.8980.7580.6943.44
EBITDA margin+11.1%+7.1%+10.3%+7.3%+12.5%+15.3%+16.8%+9.9%
Depreciation5.355.235.603.842.5716.5717.699.07
Interest1.891.952.041.060.670.720.680.33
Profit before tax88.4950.7558.1446.5472.8274.7078.4742.02
Tax26.1612.8213.2613.9518.6018.8720.2211.17
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue2,2761,7161,2961,003806814832
Revenue growth+32.6%+32.5%+29.2%+24.5%-1.0%-2.2%-
Other income28.4940.6351.2326.1014.7612.8412.99
Total expenses2,0191,5591,111878719678711
Employee cost264257241259230220217
EBITDA25715718412586.18135121
EBITDA margin+11.3%+9.2%+14.2%+12.5%+10.7%+16.7%+14.5%
Depreciation28.5839.9914.9416.2616.9520.1318.58
Interest4.491.461.200.630.951.091.14
Profit before tax25215622013483.04127114
Tax64.6840.6258.0334.8121.4433.7941.76
Net profit19117514912659.5591.7272.03
Net profit margin+8.4%+10.2%+11.5%+12.6%+7.4%+11.3%+8.7%
EPS (₹)75.0146.3064.6039.7224.6437.3228.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital5.005.005.005.005.005.005.00
Reserves & surplus868765707584506451359
Shareholders' funds (net worth)873770712589511456364
Secured loans0.000.000.000.000.000.000.00
Unsecured loans11135.734.597.218.6312.1411.84
Total debt11135.734.597.218.6312.1411.84
Total liabilities1,021821723604528475382
Assets
Gross block185218187179169160133
Net block11764.2466.6868.8674.4980.9671.53
Capital work in progress0.000.000.271.332.204.0224.24
Investments0.000.000.000.000.000.000.00
Inventories1,027548228190140160165
Sundry debtors21418515310885.8985.1983.21
Cash & bank balances449537506500448352253
Loans & advances50.3072.2745.8637.2631.1021.4241.44
Total current assets1,7401,342933835706619542
Total current liabilities968697355380329300325
Net working capital772646577455377319218
Total assets1,021821723604528475382
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash53650650044835283.50173
Net cash from operating activities(15.14)65.3627.8758.2910110587.42
Net cash from investing activities18.6930.8021.7418.114.74173(171)
Net cash from financing activities(91.97)(65.59)(44.38)(24.48)(9.46)(8.97)(6.36)
Net change in cash(88.42)30.575.2351.9296.08269(89.74)
Closing cash449537506500448352253
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+32.6%+32.5%+29.2%+24.5%-1.0%-2.2%-
EBITDA growth+63.4%-14.8%+47.7%+44.9%-36.4%+12.2%-
PBT growth+61.3%-28.8%+63.7%+61.5%-34.7%+11.5%+56.8%
Net income growth+9.2%+17.5%+18.1%+112.0%-35.1%+27.3%-
Revenue CAGR (3Y)+31.4%+28.7%+16.8%+6.4%+3.4%+12.5%+15.2%
EBITDA CAGR (3Y)+27.2%+22.2%+10.8%+1.1%+6.5%+43.0%+48.4%
Profitability & leverage
Net income margin+8.2%+6.7%+12.5%+9.9%+7.7%+11.5%+8.7%
Return on capital employed+27.9%+32.9%+33.3%+30.5%+16.8%+29.9%+33.6%
Return on net worth+22.8%+23.6%+24.8%+23.0%+12.7%+22.7%+21.7%
Debt / equity0.090.030.010.010.020.030.02
Long-term debt / equity0.080.020.000.010.010.020.01
Interest cover1.971.250.710.581.370.951.12
Efficiency & per share
Fixed asset turnover11.318.487.075.774.905.566.58
Inventory turnover2.894.426.206.075.375.015.87
Debtors turnover11.4210.169.9410.379.429.6610.21
EPS (₹)75.0146.3064.6039.7224.6437.3228.88
Dividend per share (₹)36.0032.0024.0016.0010.002.001.00
Book value per share (₹)349.12308.14284.77235.48204.56182.47145.78

Investments & Acquisitions by Astrazeneca

Astrazeneca has strategically engaged in corporate development activities, having acquired 23 companies. Notable acquisitions include Acerta Pharma, Alexion and Amolyt Pharma.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Modella
Develops AI models for pathology diagnostics and biomedical image analysis.
modella.aiBoston, United States2024Jan 2026••••
EsoBiotec
Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. This involves engineering immune cells directly within the patient's body, eliminating the need for complex ex vivo manufacturing and reducing the risks associated with traditional cell therapies. The company utilizes a proprietary vector platform to enable single-injection, off-the-shelf treatments, simplifying treatment logistics and reducing costs. The therapies are designed to minimize immune rejection and graft-versus-host disease, improving patient accessibility and quality of life. The platform is scalable, ensuring high-yield and high-purity production.
esobiotec.com2020Mar 2025$1B
Fusion Pharma
Targeted alpha therapeutics for cancer treatment are developed.
fusionpharma.comHamilton, Canada2014Mar 2024$2.4B
Amolyt Pharma
Peptide therapeutics are developed for rare endocrine and metabolic disorders.
amolytpharma.comEcully, France2015Mar 2024$1.05B
Gracell
Gracell is focused on developing innovative CAR-T cell therapies.
gracellbio.comShanghai, China2017Dec 2023$1.2B
Icosavax
Developer of computationally designed VLP vaccines for treating multiple infections
icosavax.comSeattle, United States2017Dec 2023$1.1B
CinCor
Therapeutics for cardio-renal diseases, including hypertension treatments, are developed.
cincor.comCincinnati, United States2018Jan 2023$1.3B
Neogene Therapeutics
T-cell therapies targeting neo-antigens in cancer cells are developed.
neogene.comNew York, United States2018Nov 2022••••
TeneoTwo
Developer of therapeutics for the treatment of cancer
United States0Jul 2022$100M
Caelum Biosciences
Chimeric monoclonal antibodies for AL Amyloidosis treatment are developed.
caelumbio.comNew York, United States2017Sep 2021••••
Premium access

Complete acquisition details for Astrazeneca

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Astrazeneca

14 dated milestones of Astrazeneca across 113 years, from founding to its latest funding, stage changes and deals.

  1. Founded Astrazeneca is founded.
  2. IPO Lists on the stock exchange (IPO).
  3. Funding First funding round of $12.0M.
  4. Acquisition Acquires Caelum Biosciences.
  5. Funding Latest funding round, Post-IPO, of $6.1M.
  6. Acquisition Acquires TeneoTwo.
  7. Acquisition Acquires Neogene Therapeutics.
  8. Acquisition Acquires CinCor.
  9. Acquisition Acquires Icosavax.
  10. Acquisition Acquires Gracell.
  11. Acquisition Acquires Amolyt Pharma.
  12. Acquisition Acquires Fusion Pharma.
  13. Acquisition Acquires EsoBiotec.
  14. Acquisition Acquires Modella.

Web traffic of Astrazeneca

The website of Astrazeneca (astrazeneca.com) receives about 1.3M visits a month and ranks #48,983 among all websites worldwide, #1,270 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    1.3M

    ▲ 19.3% vs previous month

  • Unique visitors
    383.5K

    per month

  • Global rank
    #48,983

    among all websites

  • Category rank
    #1,270

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Astrazeneca. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
astrazeneca-us.com
astrazeneca-us.com
100%
#659,648–
Novartis
novartis.com
97%
948.8K#58,822View details
Pfizer
pfizer.com
97%
1.9M#24,984View details
PhRMA
phrma.org
81%
63.3K#555,565View details
Merck
merck.com
79%
656.8K#78,842View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 40 similar websites and full traffic analytics for Astrazeneca

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 40 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Astrazeneca

ASTRAZEN: Q2 REVENUE 7.29B RUPEES VS 5.59B (YOY)
Exchange Update • 5 days ago
ASTRAZEN: Q2 EBITDA 955.7M RUPEES VS 751.8M (YOY); Q2 EBITDA MARGIN 13.11% VS 13.45% (YOY)
Exchange Update • 5 days ago
ASTRAZEN: Q2 STANDALONE NET PROFIT 623.3M RUPEES VS 542.2M (YOY)
Exchange Update • 5 days ago
AstraZeneca's Bone Disease Drug Efzimfotase Alfa Fails Phase III Trial Due to High Placebo Response
https://www.clinicaltrialsarena.com/ • 29 days ago
Carterra Advances Lab-In-The-Loop Drug Discovery Through New Scientific Collaboration
Business Wire • 1 month ago
AstraZeneca Opens New R&D Centre in Cambridge, US
Hospital Management • 1 month ago
Multiply Labs Raises $75 Million Series B to Close the Gap Between Drug Discovery and Drug Manufacturing
Business Wire • 1 month ago
AstraZeneca's ETCAMAH Approval and Pipeline Activity Drive Market Expansion
PR Newswire • 1 month ago
Hong Kong needs new funding model to attract global drug makers: AstraZeneca
SCMP • 1 month ago
HUTCHMED Announces US NDA Submission for ORPATHYS® plus TAGRISSO® for MET-Driven Lung Cancer
GlobeNewswire • 1 month ago
Premium access

Complete news archive for Astrazeneca

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Astrazeneca

Astrazeneca was founded in 1913 and raised its 1st funding round 98 years after it was founded.

Astrazeneca is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.

Pascal Soirot is the CEO of Astrazeneca, as recorded in our data.

Astrazeneca has 77,642 employees.

The primary company behind Astrazeneca, Astrazeneca Pharma India Limited, reported revenue of ₹2,304 Cr for FY 2026, up 33% year on year.

AstraZeneca was established in 1913 and operates as a multinational pharmaceutical and biologics firm headquartered in Cambridge, United Kingdom. Operations span over 100 countries, with a focus on products addressing cancer, cardiovascular, gastrointestinal, infectious, neurological, respiratory, and inflammatory conditions. The company has grown through mergers and acquisitions, including Cambridge Antibody Technology in 2006 and MedImmune in 2007, achieving annual revenues of 43.85 billion in 2022.

Astrazeneca offers Enhertu and Cardiovascular Medicines.

Yes, Astrazeneca is publicly traded on NSE under the ticker symbol ASTRAZEN.

Astrazeneca has made 23 acquisitions, including Acerta Pharma, Alexion, and Amolyt Pharma.

Astrazeneca has 6 investors. Key investors include European Union, Cambridge, USAGov, Public Health Emergency, and Mission Ventures.

Astrazeneca operates through Astrazeneca Pharma India Limited.

The legal entities of Astrazeneca currently have 7 directors, including Shilpa Divekar Nirula, Ashok Revathy, Praveen Rao Akkinepally and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available